ALLOInvestor•globenewswire•
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
Sentiment:Negative (20)
Summary
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in September.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 27, 2025 by globenewswire